Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.30
0.010.78%
Last update: Oct 14, 4:00 PM
$1.29
N/A
Allogene Therapeutics Inc (ALLO) Stock Price, Quote, News & History
ALLONASDAQ
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Allogene Therapeutics (NASDAQ:ALLO) through any online brokerage.
Other companies in Allogene Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Allogene Therapeutics has a consensus price target of $7.68.
The stock price for Allogene Therapeutics (NASDAQ: ALLO) is $1.3 last updated October 14, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Allogene Therapeutics.
Allogene Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Allogene Therapeutics.
Allogene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
